Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.21.2
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents [note 5] $ 42,001 $ 35,853
Prepaid expenses and other assets 430 1,122
Total current assets 42,431 36,975
Property and equipment, net 27 42
Right-of-use assets [note 7] 94 146
Other assets and restricted cash [note 5] 227 237
License agreement [note 3 and 4] 1,752 1,864
Goodwill [note 4] 1,034 1,034
Total assets 45,565 40,298
Current liabilities:    
Accounts payable 575 332
Accrued liabilities other 193 584
Accrued clinical liabilities 3,039 453
Accrued compensation 795 1,474
Current portion of long-term obligations [note 7] 68 92
Total current liabilities 4,670 2,935
Long-term obligations [note 7] 41 77
Total liabilities 4,711 3,012
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 9,452,223 issued and outstanding at June 30, 2021 and 6,111,735 issued and outstanding at December 31, 2020, respectively. 79 76
Additional paid-in capital 120,515 97,640
Accumulated deficit (79,744) (60,434)
Accumulated other comprehensive income 4 4
Total stockholders' equity 40,854 37,286
Total liabilities and stockholders' equity 45,565 40,298
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value